Recent

% | $
Quotes you view appear here for quick access.

Apple Inc. Message Board

crecy_war_knight 468 posts  |  Last Activity: 16 hours ago Member since: Jan 25, 2007
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    ACAD nice day today !

    by paulsco 18 hours ago
    crecy_war_knight crecy_war_knight 16 hours ago Flag

    Acadia has been pulling away from the IBB for about the last 1 week. Not a major thing so far, but shows biotech investors starting to take notice.

  • crecy_war_knight crecy_war_knight 16 hours ago Flag

    Well BB have like 24 M shares so yeah they will be in the front seat. I am thinking MRK, JNJ or PFE. They got the Big bucks and I can't see them letting another smaller biotech grabbing ACAD on the cheap.

  • crecy_war_knight crecy_war_knight Jul 26, 2016 10:07 AM Flag

    What are you talking about, all companies meet with analyst. SOP especially for small companies. Come on, you know that super.

  • Reply to

    ACAD Mgmt not optimistic on ADP ? Thoughts?

    by bidcom_lives Jul 23, 2016 5:18 PM
    crecy_war_knight crecy_war_knight Jul 25, 2016 10:24 AM Flag

    Those are the words of someone from Needham, and since we don't even know what was exactly said we can't even say it's a good interpretation of what management might have said. Personally, I would doubt very much management would tell an investment company they were not enthusiastic about upcoming trial results.

  • Reply to

    Is there a buy out rumor?

    by crecy_war_knight Jul 21, 2016 10:36 AM
    crecy_war_knight crecy_war_knight Jul 22, 2016 1:12 PM Flag

    But that RLYP Buy out left some Longs in the Red, Look at the chart, most likely some bought last year Over $40. Mar 2015, High was $41.71. The Buy Out price is not a new high. Just goes to show you have to be careful of your buy points. Consider what criteria you are using when you take a long position. Acadia's Buy Out price will most likely be at a NEW HIGH...I am thinking $75-85.

  • Reply to

    well good morning

    by hardcider65 Jul 20, 2016 9:58 AM
    crecy_war_knight crecy_war_knight Jul 22, 2016 10:20 AM Flag

    Also you can go to Twitter, but there so much spam and so many shorts you would have to block 80% of the posters EVERYDAY- thats how Twitter makes their money.

  • Reply to

    well good morning

    by hardcider65 Jul 20, 2016 9:58 AM
    crecy_war_knight crecy_war_knight Jul 22, 2016 9:40 AM Flag

    Well you can go to Investor Village, my name there is GoAcadia. Its free to be a "guest".

  • Reply to

    Is there a buy out rumor?

    by crecy_war_knight Jul 21, 2016 10:36 AM
    crecy_war_knight crecy_war_knight Jul 21, 2016 11:17 AM Flag

    Wow I tried to put that up several times....

  • crecy_war_knight by crecy_war_knight Jul 21, 2016 10:36 AM Flag

    Just seems like there might be something in the works and word may have leaked.

  • crecy_war_knight by crecy_war_knight Jul 20, 2016 2:58 PM Flag

    Support/Resistance
    Type Value Conf.
    resist. 47.86 1
    resist. 41.55 2
    resist. 39.88 2
    resist. 35.97 2
    resist. 33.46 16
    supp 30.30 2
    supp 27.18 5
    supp 23.60 3
    supp 21.24 5
    supp 19.23 2
    supp 17.32 4

  • Reply to

    ACAD at $35 a Share - 7% jump - Anyone know why?

    by paul777333 Jul 20, 2016 10:15 AM
    crecy_war_knight crecy_war_knight Jul 20, 2016 1:41 PM Flag

    Upgrade survey points
    half of the respondents (55%) self-identified as early adopters, or aggressive prescribers of newly FDA approved drugs

    survey suggests a LARGER PDP population than previously modeled.Data supports robust penetration into the market

    half of respondents indicated they would use Nuplazid off-label.👍10% specifically indicating would use Nuplazid in Alzheimer’s ( thank you super trades on IV. )

  • Reply to

    well good morning

    by hardcider65 Jul 20, 2016 9:58 AM
    crecy_war_knight crecy_war_knight Jul 20, 2016 1:27 PM Flag

    Found your way back aye.

  • Reply to

    MFool Buy Out Article

    by crecy_war_knight Jul 18, 2016 3:19 PM
    crecy_war_knight crecy_war_knight Jul 18, 2016 10:05 PM Flag

    Well first of all she's not president just yet. But she talks anti-biotech, but really at least one of those times I don't blame her when Martin Shkreli raised the price of that anti-parasite drug used in some HIV patients to $750 a pill from $13.50. I don't blame Hillary one bit. But at some point later she did come out and say...." I want to cure cancer ", meaning she would aide in the fight to cure cancer. Even if she gets elected I don't see her making a dramatic anti-biotech move. Yeah she twitts and the market temporarily drops, but will she if elected try to pass price controls of drugs - I doubt it. The back lash will be biotech escaping to the EU & UK. I don't see her making that move if elected.

  • Reply to

    MFool Buy Out Article

    by crecy_war_knight Jul 18, 2016 3:19 PM
    crecy_war_knight crecy_war_knight Jul 18, 2016 4:48 PM Flag

    All that stuff you mentioned- basically has NO relationship to Acadia's research and Nuplazid. Its already an approved product and thus it can not be rejected or get an FDA CRL, have a trial halt, re-trial, outright rejection....reverse split ...lack of financing...bankruptcy...etc will NEVER OCCUR to Acadia...Total Cash 457.24M
    As far as with other atypical antipsychotic drugs, Nuplazid has a Boxed Warning alerting health care professionals about an increased risk of death associated with the use of these drugs to treat older people with dementia-related psychosis. BUT....No drug in this class is approved to treat patients with dementia-related psychosis. And of course Nuplazid is the ONLY drug indicated to treat PDP.

  • crecy_war_knight by crecy_war_knight Jul 18, 2016 3:19 PM Flag

    Poised for growth
    This Could Be the Next Big Pharma Buyout
    Once biotech M&A heats up again, Acadia, Bluebird, and Jazz could be the first targets on the list, according to our Motley Fool contributors. July 18, 2016

    Brian Feroldi: One company that's likely to be on Big Pharma's watch list is Acadia Pharmaceuticals (NASDAQ:ACAD). Acadia recently won FDA approval for its first drug, called Nuplazid, which has been approved to treat Parkinson's disease psychosis, or PDP.

    Since there aren't currently any good treatment options for PDP, Acadia should have this market all to itself. Roughly 40% of the 1 million people in the U.S. who have Parkinson's disease suffer from PDP. With a wholesale price tag of $23,400 per year, it's not hard to believe that Nuplazid could turn into a blockbuster.

    So why hasn't Big Pharma moved in on Acadia yet? It's possible that the industry is waiting to see how the drug performs on the market for a few quarters. These companies might also have reservations because during Nuplazid's late-stage trials, there was an uptick in the number of deaths among patients who used the drug compared with the control group. That fact might keep some providers from recommending the drug, which could suppress demand.

    My hunch is that the healthcare community will still embrace Nuplazid with open arms because PDP places a huge burden on caregivers, but only time will tell. In the meantime, I think Acadia's stock could be an interesting opportunity for any investor with a high tolerance for risk.

  • Reply to

    ACAD sees significant decline in short interest

    by patalanico Jul 16, 2016 11:14 AM
    crecy_war_knight crecy_war_knight Jul 18, 2016 1:18 AM Flag

    Acadia Pharmaceuticals Incorporated

    $ 33.00
    ACAD
    0.38
    Short Squeeze Ranking™
    view
    Daily Short Sale Volume
    view
    Daily Naked Short Selling List
    view
    Short Interest (Shares Short)
    17,891,400
    Short Interest Ratio (Days To Cover)
    5.7
    Short Percent of Float
    20.27 %
    Short % Increase / Decrease
    -13 %
    Short Interest (Shares Short) - Prior
    20,485,900

  • Reply to

    Noted this on Twitter

    by crecy_war_knight Jul 15, 2016 12:45 PM
    crecy_war_knight crecy_war_knight Jul 15, 2016 5:10 PM Flag

    Well I joined it about 1 yr ago and never up graded to a premium member...I guess I log in as a "guest". Its been a while.

  • Reply to

    Noted this on Twitter

    by crecy_war_knight Jul 15, 2016 12:45 PM
    crecy_war_knight crecy_war_knight Jul 15, 2016 3:37 PM Flag

    Well, Baity must be having a nice year. But, I was mostly interested in the Price Target info & Recommendations. ....I think we are going to lose many members of the old MB here due to Yahoo issues. If this MB gets closed I will join you on Investor Village, it's FREE to get a name and post. I am "GoAcadia" there. check in with me there later, I am trying to keep track of who's who.

  • crecy_war_knight by crecy_war_knight Jul 15, 2016 12:45 PM Flag

    Glenn Baity Sells 4,057 Shares of Acadia Pharmaceuticals Inc. (ACAD) Stock
    July 15th, 2016 by Jeff Wilder

    Glenn Baity sold 4,057 shares of the firm’s stock in a transaction on Monday, July 11th. The stock was sold at an average price of $35.00, for a total transaction of $141,995.00. Following the completion of the sale, the executive vice president now owns 66,978 shares of the company’s stock, valued at approximately $2,344,230. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

    Glenn Baity also recently made the following trade(s):

    On Tuesday, July 12th, Glenn Baity sold 16,000 shares of Acadia Pharmaceuticals stock. The stock was sold at an average price of $35.00, for a total transaction of $560,000.00.

    ACAD has been the subject of several recent analyst reports. Vetr upgraded shares of Acadia Pharmaceuticals from a “buy” rating to a “strong-buy” rating and set a $45.04 target price for the company in a research note on Monday, June 13th. Leerink Swann reiterated a “hold” rating on shares of Acadia Pharmaceuticals in a research note on Sunday, May 22nd. Piper Jaffray Cos. reiterated a “positive” rating and issued a $44.00 price objective on shares of Acadia Pharmaceuticals in a research note on Thursday, May 19th. Aegis reiterated a “buy” rating and issued a $54.00 price objective on shares of Acadia Pharmaceuticals in a research note on Friday, April 1st. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $49.00 price objective on shares of Acadia Pharmaceuticals in a research note on Thursday, March 31st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. Acadia Pharmaceuticals has an average rating of “Buy” and a consensus price target of $46.

  • crecy_war_knight crecy_war_knight Jul 15, 2016 11:19 AM Flag

    Well,I used it again today and it still works. But how long it will work? I think sooner or later yahoo will find a "fix" and the message boards will be gone forever. I think one of the best alternatives is Investor Village (IV). You can get on the ACAD message board for free, but they do have an upgraded membership you have to pay for. I am already on IV as "GoAcadia".

AAPL
103.10+6.43(+6.65%)10:59 AMEDT